Scientists uncover new therapeutic target for treating colorectal tumors: New study shows that mice deficient in dendritic cell immunoreceptor are resilient against colitis and colonic tumor growth

Colorectal tumors are a common adverse effect of chronic inflammation of the intestine. In a new study, researchers demonstrate that mice models with dendritic cell immunoreceptor (DCIR) protein deficiency are resistant to colonic tumors induced by dextran sodium sulfate and azoxymethane. Further, they identify an antibody that reduces colitis severity and colonic tumor growth, highlighting the potential of DCIR as a therapeutic target.

Leave a Comment